Finance

Lists
Why is IMMX down ४.५९%?
Dive Deeper
IMMX:NASDAQ
Immix Biopharma Inc
US$ ७.४८
-४.५९%
(-०.३६) 1D
US$ ७.४८
०.००% (०.००)
After hours
Closed: नोभेम्बर १६, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMMX...
Open
US$ ७.७७
High
US$ ८.०१
Low
US$ ७.४५
Mkt. cap
६२.६९ करोड
Avg. vol.
१२.३६ लाख
Volume
०.००
52-wk high
US$ १५.१०
52-wk low
US$ ३.७८
EPS
-US$ ०.८७
Beta
०.२९
Shares outstanding
८.३८ करोड
No. of employees
२१
Open
US$ ७.७७
High
US$ ८.०१
Low
US$ ७.४५
Mkt. cap
६२.६९ करोड
Avg. vol.
१२.३६ लाख
Volume
०.००
52-wk high
US$ १५.१०
52-wk low
US$ ३.७८
EPS
-US$ ०.८७
Beta
०.२९
Shares outstanding
८.३८ करोड
No. of employees
२१
News stories
From web sources and news partners
GuruFocus
GuruFocus
·
१९ घण्टा पहिले
IMMX Maintained by HC Wainwright & Co. -- Price Target Raised to $27
About Immix Biopharma Inc
CEO-
Employees२१
Founded२०१२
Headquartersलस एन्जलस, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 6 analysts giving stock ratings to IMMX in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for IMMX in the last 3 months.
Highest
Current US$ ७.४८
US$ ३०.०० (+३०१.०७%)
Average
US$ २५.६७ (+२४३.१८%)
Lowest
US$ २०.०० (+१६७.३८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ २७.००
+२६१%
11/16/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
US$ २३.००
+२०७.५%
10/29/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$ २०.००
+१६७.४%
10/20/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
US$ २४.००
+२२०.९%
10/03/2026
Gil Blum
Needham
Buy
Reiterated
US$ ३०.००
+३०१.१%
09/29/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
US$ ३०.००
+३०१.१%
09/29/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
US$ २३.००
+२०७.५%
03/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
५७.२७ लाख
५९.८० लाख
५३.३३ लाख
५५.४२ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५१.६६ लाख
४८.२३ लाख
७१.२३ लाख
१.०४ करोड
Operating expense
१.०९ करोड
१.०८ करोड
१.२५ करोड
१.५९ करोड
Total operating expenses
१.०९ करोड
१.०८ करोड
१.२५ करोड
१.५९ करोड
Operating income
-१.०९ करोड
-१.०८ करोड
-१.२५ करोड
-१.५९ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.०७ करोड
-१.०१ करोड
-१.१५ करोड
-१.३९ करोड
EBT excluding unusual items
-१.०७ करोड
-१.०१ करोड
-१.१५ करोड
-१.३९ करोड
Income tax expense
११.२७ हजार
-
१४.३२ हजार
-
Effective tax rate
-०.११%
-
-०.१२%
-
Other operating expenses
-
-
-
-
Net income
-१.०७ करोड
-१.०१ करोड
-१.१६ करोड
-१.३९ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.२८
-०.१८
-०.१८
-०.१९
Interest and investment income
२.१७ लाख
७.१७ लाख
९.१४ लाख
२०.१९ लाख
Interest expense
-
-
-
-
Net interest expenses
२.१७ लाख
७.१७ लाख
९.१४ लाख
२०.१९ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.०८ करोड
-१.०७ करोड
-१.२४ करोड
-१.५९ करोड
Gain or loss from assets sale
-
३४.१५ हजार
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू